COMP <GO>
LIVN vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
LivaNova PLC (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: LIVN 3
— MRK 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $78.97 (-2.81%) • MKT CAP: $4.48B
roic
17.30%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LIVN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LIVN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.70% | 74.80% | -7.10 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 17.30% | 20.70% | -3.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.6x | 15.3x | +0.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.87% | 3.42% | +0.45 | LIVN | /fcf-yield <GO> |
| Operating Margin | 14.40% | 34.30% | -19.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | -17.50% | 28.10% | -45.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 10.70% | 1.30% | +9.40 | LIVN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 5.19 | -2.98 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.2 | 51.7 | +6.50 | LIVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.48B | $361.02B | -$356.54B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LIVN REV | MRK REV | LIVN GROSS % | MRK GROSS % | LIVN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.39B | $65.01B | 67.7% | 74.8% | $173.3M | $12.36B |
| FY 2024 | $1.25B | $64.17B | 68.1% | 76.3% | $135.9M | $18.10B |
| FY 2023 | $1.15B | $60.12B | — | — | $74.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LIVN // BETA —
MRK // BETA 0.92